Sami holds an MSc in International Health Management from Imperial College Business School and a BSc in Biomedical Science from Kings College London. He was the winner of the Harvard M&A Simulation competition for Best Acquisition during his masters studies.

Sami brings over nine years of experience in market access strategy across pharmaceutical, MedTech, and digital health innovations spanning Europe, North America, APAC, and MENA regions. His expertise encompasses developing payer value propositions, evidence generation strategies, and HTA submissions across diverse therapeutic areas including obesity, diabetes, CKD, immunology and rare diseases.

Sami has led and supported over 50 projects, ranging from Phase III evidence generation strategies to rare disease price testing and global international market access initiatives. His experience includes extensive primary research with payers, KOLs, and patient representatives. Prior to consulting, Sami gained valuable policy experience at ABHI (Association of British HealthTech Industries), where he managed cross-industry policy groups and developed deep expertise in the NHS environment and integrated care systems.

Sami is fluent in multiple languages (Bulgarian, German, and English) and has co-authored publications on rare disease and market access across the Maghreb region. He is a trained facilitator of the NICE META (MedTech Early Technical Assessment) Tool process.

‍

“I'm passionate about helping companies unlock the full value of their healthcare assets and ensuring patients have access to life-changing innovations.”

‍